ALK1 protein may play a role in breast cancer metastasis
An investigational drug targeting ALK1 prevented disease spread in preclinical studies
2015-06-15
(Press-News.org) Background: Pietras said that although prognosis for breast cancer is relatively good when detected in its early stages, metastatic disease is the cause of 90 percent of all cancer-related deaths. Therefore, learning more about the metastatic process and finding new cures to inhibit disease spread is at the center of clinical attention.
He explained that in order for a tumor to spread, a cancer cell must detach and traverse the vascular wall to escape into the blood stream, exit the vasculature to enter the metastatic site, and colonize the new tissue. The fact that the process of escape into and from the vasculature is regulated implies that it is possible to use drugs to block this process, he said.
How the Study Was Conducted: Pietras and colleagues used multiple mouse models of breast cancer; tumor samples from 768 patients in a population-based, nested case-control study; and breast cancer gene-expression data from The Cancer Genome Atlas, to understand the role of ALK1 in breast cancer metastasis and test an ALK1 inhibitor.
Results: Using multiple mouse models of breast cancer, Pietras and colleagues found that a mouse version of the ALK1 inhibitor dalantercept prevented metastatic dissemination and that combination therapy with dalantercept and the chemotherapy docetaxel was effective in preventing the spread of the primary breast tumor to the lungs.
Next, the researchers analyzed gene-expression patterns in tumors from 768 patients in a population-based, nested case-control study. This analysis showed that expression of ALK1 was significantly associated with the incidence of metastatic disease. In order to further validate their findings, Pietras and colleagues analyzed breast cancer gene-expression data from The Cancer Genome Atlas and found that ALK1 expression correlated with the expression of well-known endothelial markers and that higher levels of ALK1 expression were an independent prognostic factor for poor survival in breast cancer patients.
Author Comment: In an interview, Pietras said, "We are investigating the role of ALK1 protein expressed by endothelial cells in promoting metastatic dissemination from primary breast tumors. Our results suggest that the presence of high levels of ALK1 in the breast tumor vasculature is a prognostic biomarker for metastatic disease. Moreover, our work encourages clinical testing of drugs blocking ALK1 in breast cancer with prevention of metastatic dissemination as the primary outcome. We are currently performing therapeutic studies with dalantercept in models of breast cancer in order to pinpoint the precise therapeutic regimen and disease stage at which the treatment is the most effective."
INFORMATION:
To interview Kristian Pietras, contact Johanna Sandahl at johanna.sandahl@med.lu.se or
+46-709-94-34-79. For a photo of Pietras, click here. For other inquiries, contact Lauren Riley at lauren.riley@aacr.org or 215-446-7155.
Main Finding(s): Breast cancer patients with high levels of the protein activin-like receptor kinase (ALK1) in the blood vessels of their tumors were more likely to develop metastatic disease. This makes inhibition of the ALK1 pathway a possible new target for the treatment of metastatic breast cancer.
Journal in Which the Study was Published: Cancer Research, a journal of the American Association for Cancer Research
Author: Kristian Pietras, PhD, the Goran and Birgitta Grosskopf professor of molecular medicine at Lund University
Funding & Disclosures: This study was funded by the European Research Council; the Swedish Research Council; the Swedish Cancer Society; the STARGET Consortium; BioCARE; Lund University; BRECT; the Karolinska Institutet and Stockholm County Council; and the Radiumhemmet, Karolinska Institutet, and Karolinska University Hospital. Pietras is an inventor on a patent pertaining to ALK1 antagonism held by the Ludwig Institute for Cancer Research Ltd., and licensed to Acceleron Pharma, a company that develops dalantercept for commercial purposes.
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
For AACR information, visit Fast Facts
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 101 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 25 conferences and educational workshops, the largest of which is the AACR Annual Meeting with almost 19,300 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.
ELSE PRESS RELEASES FROM THIS DATE:
2015-06-15
Lisbon, 15 June 2015: Women with endometriosis are at an increased risk of miscarriage and ectopic pregnancy, according to results of a huge nationwide study presented today. Moreover, women with a history of endometriosis whose pregnancies progressed beyond 24 weeks were found to be at a higher than average risk of complications, including haemorrhage (ante- and postpartum) and preterm birth.
"These results indicate that endometriosis predisposes women to an increased risk of early pregnancy loss and later pregnancy complications," said the study's first author Dr Lucky ...
2015-06-15
Medical guidance on how to care for elderly people with dementia following a hip fracture is 'sadly lacking' according to researchers at the University of East Anglia.
Almost half of all people who suffer hip fractures also have dementia. But a Cochrane Review published today reveals there is no conclusive evidence on how to care for this particularly vulnerable group.
The review, which was funded by the National Institute for Health Research (NIHR), highlights an urgent need for better research into what strategies improve post-operative care - both within hospital ...
2015-06-14
More than 60,000 Australians are estimated to have reduced or discontinued their use of prescribed cholesterol-lowering statin medications following the airing of a two-part series critical of statins by ABC TV's science program, Catalyst, a University of Sydney study reveals in the latest Medical Journal of Australia.
The analysis of the Pharmaceutical Benefits Scheme medication records of 191,000 people revealed that there was an immediate impact after Catalyst was aired in October 2013, with 14,000 fewer people dispensed statins per week than expected.
"In the eight ...
2015-06-14
EuroHeartCare is the official annual meeting of the Council on Cardiovascular Nursing and Allied Professions (CCNAP) of the European Society of Cardiology (ESC). The 2015 meeting is held 14 to 15 June in Dubrovnik, Croatia, in collaboration with the Croatian Association of Cardiology Nurses.
Ms Arbjerg Højen said: "Young VTE patients are scared of having another VTE and of dying. We treat these patients in our Thrombosis Research Unit and have seen how anxious and mentally unwell they can be, even a long time after the VTE occurs. They are troubled and have a hard ...
2015-06-13
Rome, Italy, 13 June 2015: The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA). Furthermore, treatment did not improve overall physical, social and emotional wellbeing. These findings suggest that hydroxychloroquine should no longer be routinely prescribed for patients with this form of arthritis.
OA is the most common type of arthritis, ...
2015-06-13
Rome, Italy, 13 June 2015: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.
Reducing the TNFi dose by two-thirds resulted in more flares (exacerbations of symptoms and signs) but these subsided when the higher dose of TNFi was restarted, and did not adversely affect subsequent progression of any disability. ...
2015-06-13
Time may heal all wounds, but in the case of stroke survivors, the key to better recovery is to spend more time in an intensive physical therapy program, according to a University of Florida Health study.
After a stroke, the brain and body can start recovering immediately and can show improvement up to six months afterward, said UF Health researcher Janis Daly, Ph.D. But this study focused on people who had persistent disability even a year or more after completing standard care. The study found that extensive physical therapy helped them recover motor function, even ...
2015-06-12
New ideas are bubbling up for more efficient computer memory.
Researchers at UCLA and the U.S. Department of Energy's Argonne National Laboratory announced today a new method for creating magnetic skyrmion bubbles at room temperature. The bubbles, a physics phenomenon thought to be an option for more energy-efficient and compact electronics, can be created with simple equipment and common materials.
Skyrmions, discovered just a few years ago, are tiny islands of magnetism that form in certain materials. If you wrapped one up into a sphere, its magnetic fields would ...
2015-06-12
African-American adults -- particularly women -- are much more likely to know or be related to someone behind bars than whites, according to the first national estimates of Americans' ties to prisoners.
The research, led by Hedwig Lee, University of Washington associate professor of sociology, reveals the racial inequality wrought by the U.S. prison boom, with potentially harmful consequences to families and communities left lacking social supports for raising children and managing households.
In an article published May 20 in the Du Bois Review: Social Science Research ...
2015-06-12
KNOXVILLE--The increasing use of video games is often blamed for children's lack of interest in physical activity, but a study by the University of Tennessee, Knoxville, recently published in the Games for Health Journal suggests that active video games may actually be a source of moderate or intense physical activity in children five to eight years old.
"Our study shows video games which wholly engage a child's body can be a source of physical activity," said Hollie Raynor, director of UT's Healthy Eating and Activity Laboratory and associate professor of nutrition. ...
LAST 30 PRESS RELEASES:
[Press-News.org] ALK1 protein may play a role in breast cancer metastasis
An investigational drug targeting ALK1 prevented disease spread in preclinical studies
